ACTLung™  Target Genomic Profiling for Lung Cancer


| ACTLung™: NGS Testing For Lung Cancer Patient: ACTLung™ is an NGS-based test specifically designed for lung cancer patients. ACTLung™ covers 13 druggable genes and fusion gene transcripts to provide a genomic profile and recommendations of targeted drugs approved by the U.S. FDA. | Key Features: Drug Targeted-Based Panel: Covering 13 druggable genes and fusion genes that cover targeted drugs approved by the U.S. FDA. Offering Tailored Drug Options: Analyzing SNV, InDel, and fusion gene to provide tailored drug options Pioneering Bioinformatics: Specializing in cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science, and pharmaceutical biology to provide insightful interpretation Short Turnaround Time: Providing a testing report in 8 working days.
Visit ID (prod)
ACT Genomics Co. Ltd.(Looking for distributors) Company IntroACT Genomics is a leading cancer genomic testing provider started in Taiwan in 2014. Now, we have grown and expanded into Japan, Singapore, Hong Kong, and the Southeast Asia region.With cutting-edge next-generation sequencing (NGS), proprietary bioinformatics analysis, and combined expertise in tumor biology, cancer genomics, bioinformatics, and artificial intelligence, our genomic tests provide treatment suggestions based on the tumor's genomic markup. With our tests, the doctors can formulate a personalized treatment plan to achieve a better outcome for their cancer patients.Our NGS-based TestsACTOnco® +: Tumor tissue-based (FFPE)Provides comprehensive genetic information on the potential therapeutic response (i.e. to targeted therapy, chemotherapy, immunotherapy)Incorporates pathway-based analysis for a holistic overview & therapeutic recommendations440 cancer-related genes (including 13 fusion genes)All types of solid tumors (lung, breast, colorectal, prostate, TNBC, pancreatic, ovarian, CCA, liver, glioblastoma, rare cancer, and other solid tumors)ACTHRD™:  Tumor tissue-based (FFPE)Determines BRCA 1/2, LOH, and HRD status for PARP inhibitor treatment24 HRR-related genes (including BRCA1/2)Ovarian cancer and HRD-/HRR-related cancer typesACTDrug® +:  Tumor tissue-based (FFPE)Focuses on clinically recommended biomarkers for targeted therapies40 actionable genes (including 13 fusion genes)Common cancer types: lung cancer, gastric cancer, colon cancer, prostate cancer, etc.ACTLung™: Tumor tissue-based (FFPE)Focuses on biomarkers associated with lung cancer for targeted therapy13 lung-cancer-related genes (including 8 fusion genes)Lung cancerACTMonitor® +:  Blood-based (ctDNA)Monitors disease burden and treatment response/resistance50 cancer-related genesSolid tumors (Pan-cancer)